Abstract:Ovarian cancer is the fifth leading cause of cancer death and has the highest mortality rate of all gynecologic malignancies.The majority of patients with ovarian cancer present with advanced disease(stages III-IV) only have a 5-year survival of 5%～20%.The survival of patients with stages I-II disease ranges from 60%～90%,depending on tumor grade.It suggests the importance of developing new treatment and the early diagnostic method for ovarian cancer.The folate receptor α(FRα),a 38 ku molecule,belongs to the folate receptor(FR) family with high affinity for folates.FRα is anchored to cell membranes through a glycosylphosphatidylinositol moiety and transports folates via an endocytic process.FRα exhibits the limited normal tissue distribution but is overexpressed in a spectrum of solid tumors,especially in ovarian cancer.It is reported that FRα overexpressed in >90% of ovarian cancers at levels 10-to 100-fold higher than its normal expression,and the expression level of FRα in ovarian cancers correlates with the grade of malignancy.Even in early stage of ovarian cancer,FRα could be detected.The prevalent expression of FRα in ovarian cancer,among all stages,has stimulated interest in applying it as a early diagnostics biomarker.A number of studies have examined the expression of FRa in malignant tissues by immunohistochemistry.Additionally,an immunoblot assay was employed to confirm ovarian cancer patients demonstraing elevated levels of FRa in the circulation system.Furthermore,therapeutic agents based on FRα have been developed.A humanized monoclonal antibody MORAb-003 against FRα possesses novel,growth-inhibitory functions on cells overexpressing FRα.In addition,MORAb-003 elicited robust antibody-dependent cellular cytotoxicity(ADCC) and complement-dependent cytotoxicity(CDC) in vitro,and inhibited the growth of human ovarian tumor xenografts in nude mice.The novel folate targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer.

Identification of a Peptide for Folate Receptor Alpha by Phage Display and Its Tumor Targeting Activity in Ovary Cancer Xenograft

Selection and identification of a specific peptide binding to ovarian cancer cells from a phage-displayed peptide library

In Vivo Screening with Ph . D .7 TM and Identification of Ovarian Cancer A 2780 Cell Targeted

A Novel Peptide Specifically Targeting Ovarian Cancer Identified by in Vivo Phage Display.

Folate Receptor Alpha—A Novel Approach to Cancer Therapy

Identification of a Novel Afgf-Binding Peptide with Anti-Tumor Effect on Breast Cancer from Phage Display Library

The Folate Receptor α and Ovarian Cancer

The selection and primary characterization of a 12mer peptide targeting ovarian cancer cells

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library

Protein-Labeling Fluorescent Probe for Folate Receptor α

Development of a human viable heavy chain antibody against the alpha folate receptor as a molecule for targeted application by phage display technology

Clinical Translation of Folate Receptor-Targeted Therapeutics

In Vitro Screening of Ovarian Tumor Specific Peptides from a Phage Display Peptide Library

Selection and Identification of Transferrin Receptor-Specific Peptides As Recognition Probes for Cancer Cells

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Targeted Proteomics Enables Simultaneous Quantification of Folate Receptor Isoforms and Potential Isoform-based Diagnosis in Breast Cancer

Construction and Identification of Eukaryotic Expression Vector Encoding Folate Receptor

Rational Identification of a Colorectal Cancer Targeting Peptide through Phage Display

Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug

Identification and characterization of a novel phage display-derived peptide with affinity for human brain metastatic breast cancer.